Zanco Journal of Medical Sciences
 
Skip Navigation Links
Home
Available Issues
Search
Editorial Board
Information for Authors
Review Process
Copyright
Links and Contacts
  Zanko J Med Sci:  Apr. 2018; 22 (1): 104-114

Clinical significance of fasting and postprandial lipemia in obese and non-obese subjects

Muzha M. Baqi *, Abdulqader A. Alnaqishbandi **

 

* Department of Laboratory, Kurdistan Medical Control Agency, Erbil, Iraq.

** Department of Clinical Analysis, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
 


Abstract

Background and objective: Postprandial lipemia is a risk marker for the presence or progression of cardiovascular disease. Identifying factors affecting lipoprotein metabolism in postprandial state is of interest in order to find ways for prevention of atherosclerosis and cardiovascular diseases. This study aimed to assess obesity measurements and to find out the relationship between them and postprandial lipemia and to determine postprandial lipemia in obese subjects and to compare it with fasting lipemia taking in consideration the levels of Apolipoprotein B.

Methods: A cross-sectional study was designed to examine the association between obesity and postprandial lipemia. One hundred seventy one subjects of both genders with different body mass index participated in the study. Anthropometric measurements and blood pressure were recorded for them. Lipid profile was measured twice: after 12 hours fasting, two hours postprandially.

Results: There were significant differences between different groups of patients regarding with studied parameters. Men had a higher postprandial response than did women. There were significant differences between fasting and postprandial levels of lipid profile, except for the measurement of apolipoprotein B. Therefore, the level of plasma apolipoprotein B was not affected by meal intake. The postprandial lipemia was significantly related to the measurements of obesity.

Conclusion: Apolipoprotein B can replace low-density-lipoprotein-cholesterol in lipid profile assessments. By designing equations, by doing the postprandial triglyceride test, the level of fasting plasma triglyceride and level of plasma Apolipoprotein B can be estimated.

Keywords: Postprandial lipemia; Apolipoprotein B; Metabolic Syndrome.


Reference

1. Ballantyne C, Arroll B, Shepherd J. Lipids and CVD management: towards a global consensus. Eur Heart J 2005; 26 (21):2224-31.

2. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2007; 176 (8):1113-20.

3. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting Triglycerides and Risk of Ischemic Stroke in the General Population. JAMA 2008; 300 (18):2142-52.

4. Ntyintyane LM, Panz VR, Raal FJ, Gill GV. Postprandial lipaemia, metabolic syndrome and LDL particle size in urbanised South African blacks with and without coronary artery disease. QJM 2008; 101 (2):111-9.

5. Stenger C, Hanse M, Pratte D, Mbala ML, Akbar S, Koziel V, et al. Up-regulation of hepatic lipolysis stimulated lipoprotein receptor by leptin: a potential lever for controlling lipid clearance during the postprandial phase. FASEB J 2010; 24 (11):4218-28.

6. Sandeep B, Julie EB, Rifai N, Samia M, Frank MS, Paul MR. Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in Women. JAMA 2007; 298(3):309-16.

7. Matsumoto S, Gotoh N, Hishinuma S, Abe Y, Shimizu Y, Katano Y, et al. The role of hypertriglyceridemia in the development of atherosclerosis and endothelial dysfunction. Nutrients 2014; 6(3):1236-50.

8. Paloma AV, Daniel CR, Roopa M, Liliana MH, Ivette CB, Oscar PM, et al. Factors associated with postprandial lipemia and apolipoprotein A-V levels in individuals with familial combined hyperlipidemia. BMC Endocrine Disorders 2014; 14(1):43.

9. Ridker PM. Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: Do we need to revisit the oral triglyceride tolerance test? Clin Chem 2008; 54(1):11-3.

10. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979; 60(3):473-85.

11. Zheng C, Ikewaki K, Walsh BW, Sacks FM. Metabolism of apoB lipoproteins of intestinal and hepatic origin during constant feeding of small amounts of fat. J Lipid Res 2006; 47(8):1771-9. 

12. Parthasarathy S. Lipolysis Needed for Chylomicron Uptake? Arterioscler Thromb VascBiol 2010; 30:5-6.

13. Cox-York KA, Sharp TA, Stotz SA, Bessesen DH, Pagliassotti MJ, Horton TJ. The effects of sex, metabolic syndrome and exercise on postprandial lipemia. Metabolism 2013; 62 (2): 244-54.

14. Juan FAD, Javier DL, Pablo PM, Antonio GR, Carmen M, Gracia MQN, et al. Hypertriglyceridemia Influences the Degree of Postprandial Lipemic Response in Patients with Metabolic Syndrome and Coronary Artery Disease: From the Cordioprev Study. PLoS ONE 2014; 9(5):e96297.

15. Nadia A, Boumediene KM. Effect of Overweight and Obesity on Postprandial Lipemia among the Subjects with Type 2 Diabetes. Diabetes Metab J 2012; 3(2):5.

16. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction: Circulation 2008; 118(20):2047-56.

17. Garcia-Rios A, Delgado-Lista J, Perez-Martinez P, Delgado-Casado N, Perez-Jimenez F, Lopez-Miranda J. Relevance of Postprandial Lipemia in Metabolic Syndrome. CurrVascPharmacol 2013; 11(6):920-7. 

18. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 2006; 21(1):1-6.

19. Després PJ, Poirier P, Bergeron J, Tremblay A, Lemieux I, Alméras N. From individual risk factors and the metabolic syndrome to global cardiometabolic risk. Europ Heart J Suppl 2008; 10(Supplement B):B24-33.  

20. Janghorbani M, Amini M, Willett WC, Mehdi Gouya M, Delavari A, Alikhani S, et al. First nationwide survey of prevalence of overweight, underweight, and abdominal obesity       in Iranian adults: Obesity (Silver Spring) 2007; 15 (11):2797-808.

21. Tsai AG, Williamson DF, Glick HA. Direct medical cost of overweight and obesity in the USA: a quantitative systematic review. Obes Rev 2011; 12(1):50-61.

22. Wong AT, Chan DC, Pang J, Watts GF, Barrett PH. Plasma apolipoprotein B-48 transport in obese men: a new tracer kinetic study in the postprandial state. J Clin Endocrinol Metab 2014; 99(1):E122-6.

23. Freedman DS, Kahn HS, Mei Z, Grummer-Strawn LM, Dietz WH, Srinivasan SR, et al. Relation of body mass index and waist-to-height ratio to cardiovascular disease risk factors in children and adolescents: the Bogalusa Heart Study. Am J Clin Nutr 2007; 86(1):33-40.

24. Kumar P. A Hypothetical Index for Adiposity “Body Mass Abdominal Index”- That will predict Cardiovascular disease risk factors in Children. Rom J Pediatr 2010; 59(1):33-5.

25. Ulijaszek SJ, Henneberg M, Henry CJ. One reason why waist-to-height ratio is usually better related to chronic disease risk and outcome than body mass index [Abstract]. Int J Food SciNutr 2013; 64(3):269-73.

26. Schwander F, Kopf-Bolanz KA, Buri C, Portmann R, Egger L, Chollet M, et al. A Dose-Response Strategy Reveals Differences between Normal-Weight and Obese Men in Their Metabolic and Inflammatory Responses to a High-Fat Meal. J Nutr 2014; 144(10):1517-23.

27. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events [Abstract]. Circulation 2008; 118(10):993-1001.

28. Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009; 55(3):407-19.

29. Jacobson TA, Harper CR. Using Apolipoprotein B to Manage Dyslipidemia–Reply–I. Mayo Clin Proc 2010; 85 (8):769-71.

30. Chang JG, Paulson CP, Smith RF. Apolipoproteins for Cardiovascular Risk Assessment. Am Fam Physician 2014; 89(8):662A- B.

31. Sautin YY, Johnson RJ. Uric acid: the oxidant–antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 2008; 27(6):608-19.

32. Samimi A, Ramesh Sh, Turin TC, MacRae JM, Sarna MA, Reimer RA, et al. Serum uric acid level, blood pressure, and vascular angiotensin II responsiveness in healthy men and women. Physiological Reports 2014: 2(12):e12235.

33. Boudewijn K, Jan WFE, Manuel CC. Dyslipidemia in Obesity: Mechanisms and Potential Targets. Nutrients 2013; 5(4):1218-40.